CAR T-Cells will surely be the hot topic both on a clincial and commercial standpoint. More to follow!

Back in Chicago for another exciting ASCO meeting. While we still have to wait before seeing the next generation IOs and IOs combinations, ASCO2018 is expected to deliver great results for some small molecule targeted therapies! Please enquire if you have a question.

For your business development, ONKOS will be investigating new MOAs and promising drug candidates with a particular interest in emerging IOs.